▶ 調査レポート

日光角化症治療の世界市場:成長・動向・市場規模予測(2020-2025)

• 英文タイトル:Actinic Keratosis Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

Mordor Intelligenceが調査・発行した産業分析レポートです。日光角化症治療の世界市場:成長・動向・市場規模予測(2020-2025) / Actinic Keratosis Treatment Market - Growth, Trends, and Forecast (2020 - 2025) / D0-MOR-AP0011資料のイメージです。• レポートコード:D0-MOR-AP0011
• 出版社/出版日:Mordor Intelligence / 2020年4月20日
• レポート形態:英文、PDF、105ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:健康管理
• 販売価格(消費税別)
  Single User¥480,250 (USD4,250)▷ お問い合わせ
  Team User¥536,750 (USD4,750)▷ お問い合わせ
  Corporate License¥847,500 (USD7,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは、日光角化症治療の世界市場について調査・分析した資料で、日光角化症治療の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。

The Actinic Keratosis Treatment Market is expected to register a CAGR of 5.3% during the forecast period. Actinic keratosis is a rough and often bumpy patch or lesion that forms on the skin. This condition sometimes called solar keratosis or senile keratosis which enlarges slowly and usually causes no signs or symptoms other than a patch or small spot on the skin. These patches take years to develop, usually first appearing in people over 40 years of age. Actinic keratosis is more common in older people with pale-colored eyes, fair skin, and red or blonde hair who burn easily and do not tan well. Some actinic keratosis may develop into an invasive form of skin cancer called squamous cell carcinoma (SCC). Progression of squamous cell carcinoma (SCC) may be indicated by growth, discomfort/tenderness, and persistent ulceration or bleeding.
According to a study report by J. Welzel et al., published in British Journal of Dermatology 2019, estimates more than 50% of the light‐skinned population is affected with actinic keratosis during their lifetime. Actinic keratosis is the third most common factor for United States patients to consult a dermatologist. In addition, as per the Skin Cancer Foundation, more than 15,000 Americans die each year from squamous cell carcinoma.

Furthermore, increasing prevalence of actinic keratosis, growing demand for minimally invasive procedures and increasing research and development for development of novel therapies are the key driving factors in actinic keratosis treatment market.

Key Market Trends

Topical Medications Segment is Expected to Hold a Major Market Share in the Actinic Keratosis Treatment Market

The topical medications segment holds a significant market share in the actinic keratosis treatment market and is anticipated to show a similar trend over the forecast period due to the easy availability of products, high target specificity and have a lower risk of scarring. Some of the US Food and Drug Administration (FDA) approved medications for the treatment of actinic keratoses are topical fluorouracil, imiquimod, diclofenac, ingenol mebutate, and combination treatment with medications. As per study report published in British Medical Journal 2019, in England, the prevalence of actinic keratoses was about 15% in men and 5.9% in women above 40 years of age, this prevalence was elevated to 34.1% and 18.2% for men and women, respectively, in patients older than 70 years. Actinic keratosis is considered precancerous because a cutaneous squamous cell carcinoma may arise from actinic keratosis. As the number of actinic keratosis increases the chance of developing squamous cell carcinoma increases. Furthermore, promising pipeline drugs and high adoption of combination treatment are the key driving factors in the topical medications segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global actinic keratosis treatment market due to growing awareness about the occurrence of actinic keratosis and associated risk of squamous cell carcinoma in this region. According to the American Academy of Dermatology Association, estimates that more than 40 million Americans develop actinic keratoses (AKs) each year. In addition, about 60% of the Americans above 40 years of age, actinic keratosis is predisposed to develop having at least 1 actinic keratosis lesion. Furthermore, the presence of well-established healthcare infrastructure and increasing healthcare spending is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Actinic Keratosis Treatment Market is Consolidated competitive and consists of a few major players. Some of the prominent players operating in the actinic keratosis treatment market are Bausch Health Companies Inc, LEO Pharma A/S, Almirall, S.A., Biofrontera AG, Sun Pharmaceutical Industries Limited, 3M Company, Galderma SA, Alma Lasers, Novartis AG and Hill Dermaceuticals, Inc.

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– 3 months of analyst support

レポート目次

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Actinic Keratosis Worldwide
4.2.2 Growing Demand for Minimally Invasive Procedures
4.2.3 Favorable Reimbursement Policies
4.3 Market Restraints
4.3.1 Risk Factors Associated With Available Treatment Options
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Therapy
5.1.1 Topical Medications
5.1.1.1 Fluorouracil
5.1.1.2 Imiquimod
5.1.1.3 Ingenol Mebutate
5.1.1.4 Other Medications
5.1.2 Procedures
5.1.2.1 Photodynamic Therapy
5.1.2.2 Laser
5.1.2.3 Other Procedures
5.2 By End User
5.2.1 Hospitals and Oncology Centers
5.2.2 Dermatology Clinics
5.2.3 Other End users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bausch Health Companies Inc
6.1.2 LEO Pharma A/S
6.1.3 Almirall, S.A.
6.1.4 Biofrontera AG
6.1.5 Sun Pharmaceutical Industries Limited
6.1.6 3M Company
6.1.7 Galderma SA
6.1.8 Alma Lasers
6.1.9 Novartis AG
6.1.10 Hill Dermaceuticals, Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS